Bowel cancer drug move criticised
Campaigners have condemned a decision to turn down a bowel cancer drug for use on the NHS in England and Wales.
The health watchdog NICE says the cost of avastin - at about £21,000 per patient - does not justify its benefits.
It offers patients with advanced bowel cancer the chance of a few extra weeks or months of life.
Branwen Jeffreys reports.